A Phase 1 Study Evaluating A Second Generation Antisense Oligonucleotide (OGX-427) That Inhibits Heat Shock Protein 27 (Hsp27).
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2017
At a glance
- Drugs Apatorsen (Primary) ; Docetaxel
- Indications Bladder cancer; Breast cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer
- Focus Adverse reactions
- Sponsors OncoGenex Technologies
- 10 Jun 2017 Biomarkers information updated
- 18 Feb 2016 Results published in the Annals of Oncology.
- 07 Jan 2013 Planned end date changed from 1 Dec 2011 to 1 Apr 2013 as reported by ClinicalTrials.gov.